3.27

5.65% 0.175

After Hours: 3.30 0.03 +0.92%

Autolus Therapeutics Plc Adr (AUTL)

Overview News Price History Option Chain Financials Discussions Forecast

Autolus Therapeutics Plc Adr stock is traded at $3.27, with a volume of 1.60M. It is up +5.65% in the last 24 hours and down -26.35% over the past month. Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Previous Close:

$3.095

Open:

$3.13

24h Volume:

1.60M

Relative Volume:

1.16

Market Cap:

$872.88M

Revenue:

Net Income/Loss:

$-208.38M

P/E Ratio:

-2.7479

EPS:

-1.19

Net Cash Flow:

$-156.57M

1W Performance:

+16.79%

1M Performance:

-26.35%

6M Performance:

-16.58%

1Y Performance:

-31.59%

1-Day Range:

$3.13

$3.39

1-Week Range:

$2.69

$3.39

52-Week Range:

$2.69

$7.45

Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile

Name

Autolus Therapeutics Plc Adr

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

44 20 3829 6230

Address

THE MEDIAWORKS, LONDON

Employee

463

Twitter

Next Earnings Date

2024-12-12

Latest SEC Filings

AUTL's Discussions on Twitter

Compare AUTL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUTL Autolus Therapeutics Plc Adr	3.27	872.88M	0	-208.38M	-156.57M	-1.19
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Upgrade	Goldman	Neutral → Buy
Nov-15-24	Upgrade	Redburn Atlantic	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Buy
Mar-27-23	Resumed	Wells Fargo	Overweight
Mar-17-23	Initiated	Bryan Garnier	Buy
Jun-14-21	Upgrade	Jefferies	Hold → Buy
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-20	Resumed	H.C. Wainwright	Buy
Jul-31-20	Initiated	JP Morgan	Overweight
Jul-22-20	Initiated	SunTrust	Buy
Apr-22-20	Initiated	Mizuho	Buy
Sep-23-19	Initiated	Needham	Buy
May-17-19	Reiterated	H.C. Wainwright	Buy
Oct-24-18	Initiated	H.C. Wainwright	Buy

View All

Autolus Therapeutics Plc Adr Stock (AUTL) Latest News

Nov 19, 2024

These Numbers Prove Just How Vibrant The Ocugen Inc (NASDAQ: OCGN) Stock Has Been - Stocks Register

Nov 19, 2024

Nov 15, 2024

Autolus stock upgraded as obe-cel approval drives optimism for commercial potential - Investing.com

Nov 15, 2024

Nov 12, 2024

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Barchart

Nov 12, 2024

Nov 06, 2024

Does MP Materials Corporation (NYSE: MP) Still Need To Convince Analysts? - Stocks Register

Nov 06, 2024

Hafnia Ltd (NYSE: HAFN) Drops -3.00%, Turning Investors Away - Stocks Register

Nov 06, 2024

Oct 17, 2024

Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy - Yahoo Finance

Oct 17, 2024

Oct 16, 2024

Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts - Yahoo Finance

Oct 16, 2024

Oct 14, 2024

PDD Holdings Inc ADR (NASDAQ: PDD) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register

Oct 14, 2024

What Do Wall Street Analysts Think About Moderna Inc (NASDAQ: MRNA) Stock? - Stocks Register

Oct 14, 2024

Before You Invest, Make Sure You Check This Autolus Therapeutics plc ADR (NASDAQ: AUTL) Analysis - Stocks Register

Oct 14, 2024